Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.

Rudin CM, Hong K, Streit M.

J Thorac Oncol. 2013 May;8(5):e41-2. doi: 10.1097/JTO.0b013e31828bb1b3. No abstract available.

2.

EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.

Kim SM, Kim H, Jang KW, Kim MH, Sohn J, Yun MR, Kang HN, Kang CW, Kim HR, Lim SM, Moon YW, Kim JH, Paik S, Cho BC.

Mol Cancer Ther. 2016 Jul;15(7):1627-36. doi: 10.1158/1535-7163.MCT-15-0375. Epub 2016 May 11. Retraction in: Mol Cancer Ther. 2017 Oct;16(10 ):2326.

3.

Dabrafenib Active in Rare NSCLC Subtype.

[No authors listed]

Cancer Discov. 2016 Jul;6(7):OF4. doi: 10.1158/2159-8290.CD-NB2016-062. Epub 2016 May 20.

4.

Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.

Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M.

Lung Cancer. 2015 Jan;87(1):85-7. doi: 10.1016/j.lungcan.2014.11.008. Epub 2014 Nov 18.

PMID:
25466451
5.

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.

Tissot C, Couraud S, Tanguy R, Bringuier PP, Girard N, Souquet PJ.

Lung Cancer. 2016 Jan;91:23-8. doi: 10.1016/j.lungcan.2015.11.006. Epub 2015 Nov 15.

PMID:
26711930
6.

Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.

Jones S.

Pharmacogenomics. 2014 May;15(7):903-4. No abstract available.

PMID:
25090664
7.

[Molecular pathology of lung cancer: key to personalized medicine].

Cheng L, Li Y, Zhang SB, Teng XD.

Zhonghua Bing Li Xue Za Zhi. 2012 Oct;41(10):715-20. doi: 10.3760/cma.j.issn.0529-5807.2012.10.019. Review. Chinese. No abstract available.

PMID:
23302321
8.

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.

Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, Wen X, Liu D, Shi H, Yuan J, Liu J, Liu B.

Cell Death Dis. 2013 Sep 26;4:e814. doi: 10.1038/cddis.2013.312.

9.

Molecular alterations in non-small cell lung carcinomas of the young.

VandenBussche CJ, Illei PB, Lin MT, Ettinger DS, Maleki Z.

Hum Pathol. 2014 Dec;45(12):2379-87. doi: 10.1016/j.humpath.2014.08.005. Epub 2014 Sep 2.

PMID:
25288236
10.

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H, Dobrovic A, Tebbutt N, Cebon J.

J Clin Oncol. 2013 Dec 10;31(35):e448-51. doi: 10.1200/JCO.2013.50.4118. Epub 2013 Nov 4. No abstract available.

PMID:
24190114
11.

The impact of genomic changes on treatment of lung cancer.

Cardarella S, Johnson BE.

Am J Respir Crit Care Med. 2013 Oct 1;188(7):770-5. doi: 10.1164/rccm.201305-0843PP. Review.

12.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33. doi: 10.1073/pnas.1203530109. Epub 2012 Jul 6.

13.

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.

Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, Yu Y, Choyke P, Turkbey B, Raffeld M, Xi L, Steinberg SM, Wright JJ, Kummar S, Gutierrez M, Giaccone G.

Clin Cancer Res. 2011 Mar 1;17(5):1190-9. doi: 10.1158/1078-0432.CCR-10-2331. Epub 2011 Jan 11.

14.

Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.

Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A, Suzuki K, Asamura H, Furuta K, Kohno T, Kushima R.

Ann Oncol. 2014 Jan;25(1):138-42. doi: 10.1093/annonc/mdt495. Epub 2013 Dec 1.

PMID:
24297085
15.

ALK, lung cancer, and personalized therapy: portent of the future?

Garber K.

J Natl Cancer Inst. 2010 May 19;102(10):672-5. doi: 10.1093/jnci/djq184. Epub 2010 May 11. No abstract available.

PMID:
20460631
16.

Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.

Carneiro JG, Couto PG, Bastos-Rodrigues L, Bicalho MA, Vidigal PV, Vilhena A, Amaral NF, Bale AE, Friedman E, De Marco L.

Genet Res (Camb). 2014;96:e002. doi: 10.1017/S0016672314000032. Epub 2014 Mar 5.

PMID:
24594201
17.

Cancer: A Ras and NF-kappaB pas de deux.

Chenette EJ.

Nat Rev Drug Discov. 2009 Dec;8(12):932. doi: 10.1038/nrd3060. No abstract available.

PMID:
19967799
18.

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M.

Cancer Genet. 2013 Jan-Feb;206(1-2):26-31. doi: 10.1016/j.cancergen.2012.12.003. Epub 2013 Jan 10.

PMID:
23313110
20.

Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.

Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, Cignarelli M, Landriscina M.

J Clin Endocrinol Metab. 2012 Jun;97(6):E898-906. doi: 10.1210/jc.2011-3269. Epub 2012 Mar 22.

PMID:
22442268

Supplemental Content

Support Center